History

2002

Stefano Buono founded AAA as a “spin-off” of the CERN.

2003

Built first radiopharmaceutical laboratory in the Technoparc of Saint-Genis-Pouilly (France).

2004

Achieved first Marketing Authorization to commercialize GLUSCAN® in Switzerland.

2006

Completed construction of second radiopharmaceutical production plant in Venafro (Molise, Italy).

2007

Completed construction of third radiopharmaceutical production plant in the Silvano Fumero Bioindustry park in Ivrea (Piedmont, Italy).

2008

Completed construction of fourth radiopharmaceutical production plant in Troyes (France) to produce GLUSCAN® and PET Investigational Medical Products (IMP).

2008

Completed construction of fifth radiopharmaceutical production plant in Béthune (France) to produce GLUSCAN® and PET Investigational Medical Products (IMP).

2008

Signed exclusive license agreement with Bracco Diagnostics Inc. for distribution of CARDIOGEN-82® (Rb-82 generator for Cardiac PET) in Europe.

2009

Completed acquisition of Gipharma, an Italian pharmaceutical contract manufacturer for injectable and freeze-dried products.

2009

Started construction of two radiopharmaceutical production plants in Meldola (Forlì, Italy) and in “La Almunia de Doña Godina” (Zaragoza, Spain).

2009

Signed exclusive license agreement with IASON for manufacture and distribution of F18 PET diagnostic products.

2010

Made initial investment in Atreus Pharmaceuticals Corporation, a Canadian biopharmaceutical company headquartered in Ottawa.

2010

Acquired BioSynthema Inc., a U.S. molecular nuclear medicine discovery company based in St. Louis, Missouri.

2011

Raised €40 million from existing and new investors to advance and grow pipeline and expand PET manufacturing network.

2011

Acquired FabOvar, a humanized monoclonal antibody fragment from Dompé.

2011

Established third-party manufacturing agreement with GE Healthcare.

2012

Initiated global Phase 3 study of lutetium Lu 177 dotatate (Lutathera®).

2012

Established direct presence in Germany with acquisition of majority stake in Umbra medical AG, a German radiopharmaceutical company.

2012

AAA’S CELEBRATES 10 YEAR ANNIVERSARY.

2012

Acquired fully operational PET production laboratory in Porto, Portugal.

2013

Strengthened position in Spain with acquisition of two radiopharmaceutical companies, Barnatron and Catalana De Dispensación, S.A. (Cadisa).

2013

Signed new third-party PET manufacturing agreements with Eli Lilly and GE Healthcare.

2013

Entered Polish market following agreement with University of Warsaw.

2013

Completed construction of new global headquarters in Saint-Genis-Pouilly, France.

2014

Raised €41 million to accelerate international expansion, including an increased presence in U.S., and to support clinical trials.

2014

Received orphan drug designation from FDA and EMA for gallium Ga 68 dotatate.

2014

Entered UK and Irish nuclear medicine markets with the acquisition of Imaging Equipment Ltd. (IEL).

2014

Established U.S. subsidiary with an office in New York City.

2014

AAA starts commercial operations in 3 new production sites: Warsaw, Bonn, Marseille.

2015

Raised €23 million in a crossover financing with U.S.-based healthcare institutions.

2015

Announced Phase 3 NETTER-1 study evaluating lutetium Lu 177 dotatate (Lutathera) in patients with advanced midgut NETS met its primary endpoint.

2015

Completed $125 million Initial Public Offering and listed on the Nasdaq Global Select Market under the ticker “AAAP”.

2016

Acquired IDB Group in The Netherlands, securing supply of lutetium 177 for lutetium Lu 177 dotatate (Lutathera®), future therapeutic candidates.

2016

Signed exclusive license with Johns Hopkins University for PSMA receptor ligands for prostate cancer.

2016

Opened Expanded Access Program in U.S. for lutetium Lu 177 dotatate (Lutathera®).

2016

Expanded presence in Germany with acquisition of two production sites in Erlangen and Munich.

2016

FDA approved gallium Ga 68 dotatate (NETSPOT®) for PET imaging of NETs in adult and pediatric patients.

2016

Expanded theragnostic pipeline with NEOBOMB1 for gastrointestinal stromal tumors, prostate cancer and breast cancer.

2016

Established first U.S. distribution and manufacturing site in Millburn, New Jersey.

2016

Raised $172.2 million from U.S.-based institutions to support ongoing operations.

2016

European Commission approved Marketing Authorization of SomaKit TOCTM for PET imaging of GEP-NETs in adults.

2017

Results of Phase 3 NETTER-1 study published in New England Journal of Medicine.

2017

AAA CELEBRATES 15-YEAR ANNIVERSARY.

2017

Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors.

2017

First clinical study with lutetium Lu 177 dotatate (Lutathera®) started in Japan.